Compare · GKOS vs MDLN
GKOS vs MDLN
Side-by-side comparison of Glaukos Corporation (GKOS) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GKOS and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.86B, about 4.4x GKOS ($10.70B).
- MDLN has been more active in the news (12 items in the past 4 weeks vs 6 for GKOS).
- Both have 25 recent analyst ratings on file.
- Company
- Glaukos Corporation
- Medline Inc.
- Price
- -
- -
- Market cap
- $10.70B
- $46.86B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- 2025
- News (4w)
- 6
- 12
- Recent ratings
- 25
- 25
Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Latest GKOS
- Director Kliman Gilbert H exercised 2,500 shares at a strike of $25.77 and sold $475,000 worth of shares (2,500 units at $190.00) (SEC Form 4)
- Glaukos Announces Participation in Wells Fargo Healthcare Conference
- PRESIDENT & COO Gilliam Joseph E sold $10,784,659 worth of shares (60,000 units at $179.74) and exercised 60,000 shares at a strike of $52.94 (SEC Form 4)
- SVP & CHIEF FINANCIAL OFFICER Thurman Alex R. sold $3,602,600 worth of shares (20,000 units at $180.13) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $33.81 (SEC Form 4)
- Director Wen Leana sold $88,006 worth of shares (525 units at $167.63), decreasing direct ownership by 2% to 21,092 units (SEC Form 4)
- Glaukos Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Glaukos Corporation
- Glaukos Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Glaukos Announces Second Quarter 2026 Financial Results
- UBS initiated coverage on Glaukos
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.